These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15134285)

  • 1. Rimonabant Sanofi-Synthélabo.
    Fernandez JR; Allison DB
    Curr Opin Investig Drugs; 2004 Apr; 5(4):430-5. PubMed ID: 15134285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
    Srivastava BK; Joharapurkar A; Raval S; Patel JZ; Soni R; Raval P; Gite A; Goswami A; Sadhwani N; Gandhi N; Patel H; Mishra B; Solanki M; Pandey B; Jain MR; Patel PR
    J Med Chem; 2007 Nov; 50(24):5951-66. PubMed ID: 17979261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
    Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecule of the month. Rimonabant hydrochloride.
    Drug News Perspect; 2004; 17(6):403. PubMed ID: 15334190
    [No Abstract]   [Full Text] [Related]  

  • 10. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
    Smith RA; Fathi Z; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Podlogar B; Taing C; Tomlinson S; Tritto T; Zhang Z
    Bioorg Med Chem Lett; 2007 Feb; 17(3):673-8. PubMed ID: 17107792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
    Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR
    Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor antagonists and obesity.
    Black SC
    Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
    Doggrell SA
    Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
    [No Abstract]   [Full Text] [Related]  

  • 17. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.
    Spivey AC; Tseng CC; Jones TC; Kohler AD; Ellames GJ
    Org Lett; 2009 Oct; 11(20):4760-3. PubMed ID: 19778010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.
    Dow RL; Hadcock JR; Scott DO; Schneider SR; Paight ES; Iredale PA; Carpino PA; Griffith DA; Hammond M; Dasilva-Jardine P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5351-4. PubMed ID: 19683918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.